Vol. 5 No. 4 (2025)
Reimbursement Reviews

Ferric Carboxymaltose (Ferinject)

decorative image of the issue cover

Published April 28, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ferric carboxymaltose (Ferinject), 50 mg elemental iron per mL, vial for injection (2 mL, 10 mL, 20 mL).
  • Indication: For the treatment of iron deficiency anemia in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective. The diagnosis of iron deficiency must be based on laboratory tests.